Issuu on Google+

ReportLinker

Find Industry reports, Company profiles and Market Statistics

>> Get this Report Now by email!

Therapies and Diagnostics for Cervical Cancer Published on August 2013

Report Summary STUDY GOALS AND OBJECTIVES This report provides an overview of the current and potential global market for cervical cancer, including treatments and screening and testing technologies. The report provides comprehensive information on cervical cancer, highlighting treatment guidelines. It identifies and analyzes the key trends driving the global cervical cancer therapeutics market. The key objective is to present a comprehensive analysis of current cervical cancer'related technologies and the utilization of various therapeutic, prophylactic, screening, and diagnostic modalities. The report's focus is on cervical disorders, current treatment strategies and drugs, chemotherapy, and other treatment modalities and testing and screening methods. Important trends in the field, research, new developments, and sales forecasts by treatment and screening categories from 2012 through 2018 are provided in this report. Issues and trends addressed in this report are based on information from industry sources, regulatory and health care policies, demographics, and other factors that directly affect the cervical cancer market. The report also focuses on the treatment usage patterns in the global cervical cancer therapeutics market, the competitive landscape and emerging players, and pipeline products. It also details opportunities for future players. REASONS FOR DOING THIS STUDY This study was conducted to provide detailed information regarding prophylactics, screening, testing, and treatment options for cervical disorders and cancer. There is an increasing need for new and innovative technologies. This industry is experiencing tremendous growth. Many diseases discussed in this report are global issues, and a need exists for newer diagnostic and treatment strategies. This study looks at most types of diagnostic and treatment strategies for the clinical management of cervical disorders and related cancers. This BCC market research report will increase the awareness of current and emerging drugs and technologies for cervical cancers, including prophylactics, therapeutics, chemotherapy, and surgical therapy. INTENDED AUDIENCE This report is a detailed study of the global cervical cancer market, with key statistics on and analysis of current drugs and screening and diagnostic technologies, latest trends, market structure, market size, key drug segments, and trends in technology. This study examines the areas of market growth in cervical cancer prevention and treatment strategies from the point of view of manufacturers, product suppliers, health care providers, and consumers of cervical cancer products and services. This study will be of interest largely to the pharmaceutical and biotechnology industries, as well as clinics, hospitals, and research institutes. This report may also prove crucial for investment firms in the concerned sector. This report describes tests and prophylactics currently being used for cervical disorders; cancer diagnosis and prognosis; new developments; spending trends; and revenue prospects for technologies. The report provides market data for 2012 to 2018 and also covers commercial prospects, cervical cancer diagnostic tests, current screening methods in use, and future growth. SCOPE OF THE STUDY

Therapies and Diagnostics for Cervical Cancer (From Issuu)

Page 1/21


ReportLinker

Find Industry reports, Company profiles and Market Statistics

>> Get this Report Now by email! The scope of this study includes testing, prophylactics vaccines, screening tests and methods, and therapeutics markets for cervical cancers. The report also discusses current technologies, new technologies, cervical cancer incidence, and market projections and market share, along with latest trends and new developments. METHODOLOGY Both primary and secondary research methodologies were used in preparing this report. Secondary sources include books, newspapers, trade journals, white papers, industry portals and news, government agencies, trade associations, and paid and free databases. The base year of the report is 2012, with forecast data provided through 2018. Historical, base year, and forecast data are provided for each market segment of this report. The report provides a comprehensive review of cervical cancer, including discussion of incidence and development of the disease, drugs currently being used, and diagnostic technologies. The report also reviews technological developments, product innovations/introductions, and recent strategic industry activity of major players across various product categories. Growth rates, global incidence, and projections have been determined through a compilation of data, including past trends, future trends, demographics, incidence, mortality, products in research and development (R&D), and current product growth. Forecasts and projections were based on market trends, potential users, and mergers and acquisitions. A comprehensive and exhaustive search of the literature was conducted on cervical cancer and disorders; products; global incidence; and drug developments. Secondary sources included scientific journals and articles, textbooks, press releases, marketing literature, other product/promotional literature, annual reports, security analyst reports, and other publications. A patent search and analysis were also completed. Some informal interviews were also conducted with experts and personnel in this area at biotech and pharmaceutical companies. Other resources included academic institutions and technology and consulting companies. INFORMATION SOURCES Many companies within the industry were surveyed to obtain data for this study. Included were manufacturers and end users of products, such as pharmaceutical and biotechnical companies and research institutes. Data were gathered from various industry sources. BCC spoke with officials within the industry and consulted newsletters, company literature, product literature, and a host of technical articles, journals, indexes, and abstracts. Exhaustive investigations of databases using key terminology were completed. In addition, data were compiled from current financial, trade, and government sources. ABOUT THE AUTHOR Usha Nagavarapu is an experienced pharmaceutical professional with scientific and business development experience. She has managed preclinical discovery programs involving target identification, including investigational new drug (IND) enabling studies, and assisted out-licensing and portfolio development activities. Her strong focus areas include oncology, dermatology, and cardiovascular diseases. She has extensive experience working with early start-ups to fulfill operational obligations while minimizing overall operational cost and burden. REPORT HIGHLIGHTS This report provides: ' An overview of the global market for cervical cancer diagnostics and therapies. ' Analyses of global market trends, with data from 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018. ' A breakdown of the markets by prophylactics, screening and diagnostics, surgery, radiation therapy, and drug therapy. ' Discussion of cervical cancer biology. ' Delineation of drugs approved to treat the disease, including chemotherapeutic and immunotherapeutic. ' Evaluation of the patent landscape.

Therapies and Diagnostics for Cervical Cancer (From Issuu)

Page 2/21


ReportLinker

Find Industry reports, Company profiles and Market Statistics

>> Get this Report Now by email! ' Comprehensive profiles of key companies.

Table of Content TABLE OF CONTENTS CHAPTER 1 INTRODUCTION 2 STUDY GOALS AND OBJECTIVES 2 REASONS FOR DOING THIS STUDY 2 INTENDED AUDIENCE 2 SCOPE OF THE STUDY 3 METHODOLOGY 3 INFORMATION SOURCES 4 ABOUT THE AUTHOR 4 RELATED BCC REPORTS 4 BCC ONLINE SERVICES 4 DISCLAIMER 5 CHAPTER 2 SUMMARY 7 SUMMARY 7 SUMMARY TABLE CERVICAL CANCER: GLOBAL MARKET FOR DRUGS AND DIAGNOSTICS, THROUGH 2018 ($ MILLIONS) 7 SUMMARY FIGURE CERVICAL CANCER: GLOBAL MARKET FOR DRUGS AND DIAGNOSTICS, 2012-2018 ($ MILLIONS) 8 CHAPTER 3 OVERVIEW 10 TABLE 1 MAIN TYPES OF CANCER AND MORTALITY 10 FIGURE 1 MAIN TYPES OF CANCER AND MORTALITY 10 TABLE 2 CANCER: KEY FACTS 11 TABLE 3 PREVENTION STRATEGIES 11 EARLY DETECTION 12 EARLY DIAGNOSIS 12 SCREENING 12 TABLE 4 CURRENT SCREENING METHODS 12 CANCER TREATMENT 12 TABLE 5 NONCOMMUNICABLE DISEASES ACTION PLAN 13 CERVICAL CANCER 13 TABLE 6 HISTORY 14 CERVICAL CANCER RESEARCH AND TREATMENT 14 SENTINEL LYMPH NODE BIOPSY 14 HUMAN PAPILLOMAVIRUS (HPV) VACCINES 14

Therapies and Diagnostics for Cervical Cancer (From Issuu)

Page 3/21


ReportLinker

Find Industry reports, Company profiles and Market Statistics

>> Get this Report Now by email! TARGETED THERAPY 15 HYPERTHERMIA 15 DRUG TREATMENT OF PRECANCERS 15 SYMPTOMS 16 TABLE 7 CERVICAL CANCER SYMPTOMS 16 TABLE 8 ADVANCED CERVICAL CANCER SYMPTOMS 16 DIAGNOSIS 16 TABLE 9 DIAGNOSIS OF CERVICAL CANCER 17 TABLE 10 RISK FACTORS FOR CERVICAL CANCER 17 TREATMENT 18 TABLE 11 CERVICAL CANCER STAGING 18 PROGNOSIS 19 CHAPTER 4 CERVICAL CANCER: BIOLOGY 21 CERVIX 21 CAUSES 21 HUMAN PAPILLOMAVIRUS 22 TABLE 12 HUMAN PAPILLOMAVIRUS: TYPES 23 SYMPTOMS OF GENITAL WARTS 24 HUMAN PAPILLOMAVIRUS (HPV) INFECTIONS AND TRANSMISSION 24 E6/E7 PROTEINS 26 VACCINES 28 TREATMENT OF GENITAL WARTS 29 CANCER SUBTYPES 29 TABLE 13 HISTOLOGIC SUBTYPES OF INVASIVE CERVICAL CARCINOMA 30 TABLE 14 NON-CARCINOMA MALIGNANCIES THAT CAN RARELY OCCUR IN THE CERVIX 30 NOVEL BIOMARKERS IN CERVICAL CANCER PREVENTION 30 E6/E7 MESSENGER RNA (MRNA) DETECTION 30 P16INK4A 30 OTHER BIOMARKERS 31 EPIGENETIC MARKERS: DNA METHYLATION 31 VIRAL METHYLATION 31 CHROMOSOMAL ABNORMALITIES 32 MICRORNAS (MIRNAS) 32 BIOMARKERS AND THE FUTURE 33 CHAPTER 5 SCREENING 35 WHY SCREENING IS CRITICAL 35 CERVICAL CANCER SCREENING GUIDELINES 36 VACCINATION 36 CERVICAL CANCER DIAGNOSIS 36 EXAMINATION 37 COMPUTED TOMOGRAPHY 37 BIOPSY 38 PRECANCEROUS LESIONS 38

Therapies and Diagnostics for Cervical Cancer (From Issuu)

Page 4/21


ReportLinker

Find Industry reports, Company profiles and Market Statistics

>> Get this Report Now by email! CLINICAL STAGING 39 TABLE 15 THE MAJOR CATEGORIES OF THE INTERNATIONAL FEDERATION OF GYNECOLOGY AND OBSTETRICS (FIGO) CLASSIFICATION 39 LYMPH NODE EVALUATION 39 TABLE 16 THE INTERNATIONAL FEDERATION OF GYNECOLOGY AND OBSTETRICS (FIGO) STAGES 40 Additional Staging 40 LIMITATIONS OF TECHNIQUES 40 CERVICAL CANCER SCREENING 41 TABLE 17 TWO SCREENING TESTS THAT HELP PREVENT CERVICAL CANCER OR DETECT IT EARLY 41 PAP TEST 41 TABLE 18 TYPES OF SCREENING FOR CERVICAL CANCER 43 TABLE 19 PAP TEST INDICATIONS 43 TABLE 20 BETHESDA SYSTEM 45 Pap Tests: Issues 45 HUMAN PAPILLOMAVIRUS (HPV) TEST 45 Tests and Challenges 46 Procedure and Current Status 46 FDA-APPROVED HUMAN PAPILLOMAVIRUS (HPV) TESTS 47 TABLE 21 FDA-APPROVED HUMAN PAPILLOMAVIRUS (HPV) TESTS 47 Digene Hybrid Capture 2 (HC2) High-Risk HPV DNA Test 47 Cervista HPV HR and Genfind DNA Extraction Kit 48 Cervista HPV 16/18 48 cobas Human Papillomavirus (HPV) Test 48 APTIMA Human Papillomavirus (HPV) Assay 49 DIAGNOSTIC TESTS 49 Colposcopy 49 Cervical Biopsies 50 Colposcopic Biopsy 50 Endocervical Curettage (Endocervical Scraping) 50 Cone Biopsy 50 CYSTOSCOPY, PROCTOSCOPY, AND EXAMINATION UNDER ANESTHESIA 51 IMAGING STUDIES 51 CERVICAL CANCER SCREENING GUIDELINES 52 TABLE 22 CERVICAL CANCER SCREENING 52 CERVICAL CANCER SCREENING 53 Total Hysterectomy and Pap Tests: Issues 53 TABLE 23 THE ACS-ASCCP-ASCP RECOMMENDATIONS: CHANGES FROM THE PREVIOUS ACS GUIDELINES 54 TYPES OF GYNECOLOGIC TUMOR MARKERS 54 TABLE 24 IMPORTANT GYNECOLOGIC TUMOR MARKERS 55 TABLE 25 OTHER POTENTIAL GYNECOLOGIC TUMOR MARKERS 55 CLINICAL USEFULNESS OF TUMOR MARKERS 56 CONCLUSION 56 CHAPTER 6 THE TREATMENT OF CERVICAL CANCER 58

Therapies and Diagnostics for Cervical Cancer (From Issuu)

Page 5/21


ReportLinker

Find Industry reports, Company profiles and Market Statistics

>> Get this Report Now by email! CLINICAL STAGES AND PROGNOSIS 58 TREATMENT 58 RISK FACTORS 58 SCREENING PROGRAMS 58 CYTOLOGIC TESTS 59 CONVENTIONAL CYTOLOGY 59 CLASSIFICATION SYSTEM 59 TABLE 26 THE BETHESDA SYSTEM 60 CERVICAL CANCER TREATMENT STRATEGIES 61 CERVICAL CANCER OVERVIEW 62 STAGE-BASED THERAPY 62 Stage 0 Cancer 62 Stage IA1 Cancer 62 Stage IA2, IB, or IIA Cancer 62 Stage IIB, III, or IVA Cancer 63 Stage IVB and Recurrent Cancer 63 COMPLICATIONS OF THERAPY 64 Radiation-Related Complications 64 Problems Due to Surgeries 64 THERAPEUTIC STRATEGY 64 TABLE 27 DRUGS APPROVED TO TREAT CERVICAL CANCER 65 Chemotherapy 65 TABLE 28 COMMON CHEMOTHERAPY MEDICINES USED TO TREAT CERVICAL CANCER 65 Cisplatin 66 Ifosfamide (Ifex) 66 Fluorouracil (Adrucil) 66 Paclitaxel (Taxol) 66 Topotecan (Hycamtin) 66 Docetaxel 66 Gemcitabine 68 Vaccines: Inactivated, Viral 68 Human Papillomavirus Vaccine, Quadrivalent (Gardasil) 69 Human Papillomavirus Vaccine, Bivalent (Cervarix) 69 NEW AND PROMISING THERAPIES 69 DRUGS IN CLINICAL TRIALS 70 Ixabepilone 70 ADXS11-001 70 ISA101 Vaccine 70 Veliparib 70 Carcinoembryonic Antigen (CEA) 71 Olaparib 71 CHAPTER 7 CERVICAL CANCER INCIDENCE 73 CANCER WORLDWIDE-THE GLOBAL PICTURE 73 TABLE 29 POPULATION MEASURES AND CANCER INCIDENCE AND MORTALITY IN REGIONS OF THE WORLD, ESTIMATES 2008'2010 75

Therapies and Diagnostics for Cervical Cancer (From Issuu)

Page 6/21


ReportLinker

Find Industry reports, Company profiles and Market Statistics

>> Get this Report Now by email! COMMON CANCERS 76 TABLE 30 TOTAL NUMBER AND PERCENTAGES OF ALL CANCER DEATHS, WORLDWIDE, 2008 77 FUTURE TRENDS 77 TABLE 31 THE PROJECTED PERCENTAGE CHANGE IN EUROPEAN AGE-STANDARDIZED CANCER INCIDENCE RATES PER 100,000 POPULATION, U.K., 2007'2030 79 GLOBAL INCIDENCE OF CERVICAL CANCER 79 TABLE 32 POPULATION ATTRIBUTABLE FRACTION (%) 80 TABLE 33 CERVICAL CANCER: GLOBAL INCIDENCE, 2008 81 TABLE 34 GLOBAL CERVICAL CANCER: MORTALITY 2008 AND 2030* 82 RECENT BREAKTHROUGHS 83 TABLE 35 WORLDWIDE PREVALENCE OF HUMAN PAPILLOMAVIRUS (HPV) IN WOMEN WITH CERVICAL CANCER 83 CERVICAL CANCER THOUGH TIME 84 TABLE 36 CERVICAL CANCER BY CONTINENTS, 2008 ESTIMATES 85 TABLE 37 CERVICAL CANCER WORLD AGE-STANDARDIZED INCIDENCE RATES PER 100,000 POPULATION, FEMALES IN WORLD REGIONS, 2008 ESTIMATES 85 TABLE 38 CERVICAL CANCER INCIDENCE AND MORTALITY WORLDWIDE, 2008 (THOUSANDS) 86 FIGURE 2 CERVICAL CANCER INCIDENCE AND MORTALITY WORLDWIDE, 2008 (THOUSANDS) 86 TABLE 39 WORLDWIDE BURDEN OF CERVICAL CANCER BY AREA, 2008 89 TABLE 40 CHANGING TRENDS IN CANCER-SPECIFIC AGE-ADJUSTED INCIDENCE (%) 90 PREVENTION STRATEGIES 93 CERVICAL CANCER AND THE U.S. 94 TABLE 41 U.S.: ESTIMATED NEW CASES AND DEATHS FROM CERVICAL (UTERINE CERVIX) CANCER, 2012 AND 2013 94 INCIDENCE AND MORTALITY 94 TABLE 42 U.S.: INCIDENCE RATES BY RACE, 2005'2009 95 U.S. Cervical Cancer Mortality 95 TABLE 43 U.S.: DEATH RATES BY RACE, 2005-2009 95 Survival and Stage 96 TABLE 44 STAGE DISTRIBUTION AND FIVE-YEAR RELATIVE SURVIVAL BY STAGE AT DIAGNOSIS, ALL RACES, FEMALES, 2002'2008 96 TABLE 45 FIVE-YEAR OBSERVED SURVIVAL RATE 97 European Union 97 TABLE 46 CERVICAL CANCER: EUROPEAN AGE-STANDARDIZED INCIDENCE RATES PER 100,000 POPULATION AMONG FEMALES, EU27 COUNTRIES, 2008 ESTIMATES 98 FIGURE 3 CERVICAL CANCER: EUROPEAN AGE-STANDARDIZED INCIDENCE RATES PER 100,000 POPULATION AMONG FEMALES, EU27 COUNTRIES, 2008 ESTIMATES 98 U.K. 100 TABLE 47 NUMBER OF NEW CASES AND CRUDE AND EUROPEAN AGE-STANDARDIZED (AS) INCIDENCE RATES PER 100,000 POPULATION AMONG FEMALES IN U.K., 2009 100 TABLE 48 CERVICAL CANCER: AVERAGE NUMBER OF NEW CASES PER YEAR AND

Therapies and Diagnostics for Cervical Cancer (From Issuu)

Page 7/21


ReportLinker

Find Industry reports, Company profiles and Market Statistics

>> Get this Report Now by email! AGE-SPECIFIC INCIDENCE RATES PER 100,000 POPULATION AMONG FEMALES IN U.K., 2007'2009 101 TABLE 49 CERVICAL CANCER: PERCENTAGE CHANGE IN AGE-SPECIFIC INCIDENCE RATES PER 100,000 POPULATION AMONG FEMALES IN U.K., 2008'2009 102 TABLE 50 CERVICAL CANCER: ONE-YEAR, FIVE-YEAR, AND 10-YEAR CANCER PREVALENCE AMONG FEMALES IN U.K., DECEMBER 31, 2006 102 TABLE 51 NUMBER OF NEW CASES IN U.K., 2009 AND 2010 103 TABLE 52 U.K.: THE 10 MOST COMMONLY DIAGNOSED CANCERS IN FEMALES IN 1984, 2007, AND 2030 104 TABLE 53 CERVICAL CANCER: THE PROJECTED PERCENTAGE CHANGE IN EUROPEAN AGE-STANDARDIZED MORTALITY RATES PER 100,000 POPULATION IN U.K., 2010 AND 2030 104 TABLE 54 U.K.: THE 10 MOST COMMON CAUSES OF CANCER DEATH IN FEMALES IN 1990, 2010, AND 2030 105 India 106 China 107 Africa 108 TABLE 55 KEY STATISTICS IN AFRICA AND ITS REGIONS, 2008 109 TABLE 56 HUMAN PAPILLOMAVIRUS (HPV) PREVALENCE IN THE GENERAL POPULATION, 2008 110 TABLE 57 AFRICA: PREVALENCE HPV 16 AND/OR HPV 18 AMONG WOMEN WITH THE FOLLOWING CHARACTERISTICS 110 TABLE 58 INCIDENCE OF CERVICAL CANCER IN AFRICA BY REGION, 2008 111 TABLE 59 MORTALITY OF CERVICAL CANCER IN AFRICA BY REGION, 2008 111 TABLE 60 AGE-STANDARDIZED INCIDENCE RATES OF CERVICAL CANCER IN AFRICA, 2008 111 TABLE 61 AGE-STANDARDIZED MORTALITY RATES OF CERVICAL CANCER IN AFRICA, 2008 112 SCREENING AND TREATMENT APPROACHES 112 SAUDI ARABIA 113 NIGERIA 113 KENYA 114 GAMBIA 116 CANADA 116 GERMANY 116 TABLE 62 INCIDENCE OF CERVICAL CANCER IN GERMANY, WESTERN EUROPE, AND THE WORLD, 2008 (RATES PER 100,000 WOMEN PER YEAR) 117 TABLE 63 KEY STATISTICS ON GERMANY, 2010-2025 117 AUSTRALIA 117 TABLE 64 AUSTRALIA: PROJECTED COMMON CANCERS IN FEMALES, 2020 118 TABLE 65 AUSTRALIA: PROJECTED NUMBER OF NEW CERVICAL CANCER CASES AND AGE-STANDARDIZED RATES AMONG FEMALES WITH 95% PREDICTION INTERVALS, 2011-2020 119 TABLE 66 AUSTRALIA: PROJECTED CERVICAL CANCER STATISTICS, 2020 119 HONG KONG 119

Therapies and Diagnostics for Cervical Cancer (From Issuu)

Page 8/21


ReportLinker

Find Industry reports, Company profiles and Market Statistics

>> Get this Report Now by email! CONCLUSION 120 CHAPTER 8 CERVICAL CANCER DIAGNOSTICS MARKET 123 TABLE 67 WOMEN UNDERGOING CERVICAL CANCER SCREENING 123 CERVICAL CANCER SCREENING 123 CERVICAL CANCER TESTING GUIDELINES 124 CERVICAL CANCER DIAGNOSTIC TESTS MARKET 125 TABLE 68 WORLDWIDE CERVICAL CANCER DIAGNOSTIC MARKET, THROUGH 2018 ($ MILLIONS) 125 FIGURE 4 WORLDWIDE CERVICAL CANCER DIAGNOSTIC MARKET, 2012-2018 ($ MILLIONS) 125 MARKET DRIVERS 126 TABLE 69 MARKET DRIVERS 126 TABLE 70 KEY PLAYERS 127 RESTRAINTS 127 Lack of Appropriate Health Care Infrastructure in Underdeveloped and Developing Countries 128 HPV VACCINATION 129 Available Vaccines 129 WHO Recommends the Vaccine for Girls Between the Ages of 10 and 13 130 WHO Does Not Recommend the Vaccine for Boys 130 CERVICAL CANCER DIAGNOSTIC TESTS MARKET BY TEST TYPES 131 Pap Smear Test 131 TABLE 71 GLOBAL CERVICAL CANCER DIAGNOSTIC TESTS: PAP SMEAR TESTS MARKET AND FORECAST, THROUGH 2018 ($ MILLIONS) 131 FIGURE 5 GLOBAL CERVICAL CANCER DIAGNOSTIC TESTS: PAP SMEAR TESTS MARKET AND FORECAST, 2012-2018 ($ MILLIONS) 131 TABLE 72 NUMBER OF PAP SMEAR TESTS PERFORMED IN THE U.S. AND EUROPE, 2012 AND 2013 (MILLIONS) 133 Pap Tests: U.S. 133 TABLE 73 U.S.: PERCENT OF PAP SMEAR TESTS PERFORMED, 2008 AND 2010 (%) 133 TABLE 74 U.S.: PERCENT OF WOMEN WHO RECEIVE PAP SMEAR TESTS, AGE-STRATIFIED, 2008 AND 2010 (%) 134 TABLE 75 PAP TESTS ORDERED OR PROVIDED IN U.S., 2010 134 TABLE 76 PAP TESTS ORDERED OR PROVIDED AT OUTPATIENT DEPARTMENT VISITS IN U.S., 2010 135 Latest Technology 135 Canadian Market 136 Ontario Guidelines 136 Cervical Cancer and India 136 PAP TESTS: BENEFIT OR NOT' 137 TABLE 77 ABNORMALITIES OF THE CERVIX 138 GLOBAL COLPOSCOPY TESTS MARKET 138 TABLE 78 WORLDWIDE ESTIMATED NUMBER OF COLPOSCOPY PROCEDURE TESTS PERFORMED, 2012-2018 (MILLIONS) 139 FIGURE 6 WORLDWIDE ESTIMATED NUMBER OF COLPOSCOPY PROCEDURE TESTS

Therapies and Diagnostics for Cervical Cancer (From Issuu)

Page 9/21


ReportLinker

Find Industry reports, Company profiles and Market Statistics

>> Get this Report Now by email! PERFORMED, 2012'2018 (MILLIONS) 139 TABLE 79 CERVICAL CANCER COLPOSCOPY: GLOBAL MARKET AND FORECAST, THROUGH 2018 ($ MILLIONS) 140 FIGURE 7 CERVICAL CANCER COLPOSCOPY: GLOBAL MARKET AND FORECAST, 2012-2018 ($ MILLIONS) 140 TABLE 80 CERVICAL CANCER: COLPOSCOPY TESTS MARKET AND FORECAST IN U.S., THROUGH 2018 ($ MILLIONS) 140 FIGURE 8 CERVICAL CANCER: COLPOSCOPY TESTS MARKET AND FORECAST IN U.S., 2012-2018 ($ MILLIONS) 141 Biopsy 142 Types of Cervical Biopsies 142 TABLE 81 TYPES OF CERVICAL BIOPSIES 142 ENDOCERVICAL CURETTAGE (ECC) PROCEDURE MARKET 143 TABLE 82 WORLDWIDE ENDOCERVICAL CURETTAGE (ECC) PROCEDURE MARKET: SALES AND FORECAST, THROUGH 2018 ($ MILLIONS) 144 FIGURE 9 WORLDWIDE ENDOCERVICAL CURETTAGE (ECC) PROCEDURE MARKET: SALES AND FORECAST, 2012-2018 ($ MILLIONS) 144 Femasys 144 Liquid-Based Cytology 145 HPV TESTING 145 TABLE 83 WORLDWIDE HUMAN PAPILLOMAVIRUS (HPV) TESTING MARKET: SALES AND FORECAST, THROUGH 2018 ($ MILLIONS) 146 FIGURE 10 WORLDWIDE HUMAN PAPILLOMAVIRUS (HPV) TESTING MARKET: SALES AND FORECAST, 2012-2018 ($ MILLIONS) 146 TABLE 84 KEY PLAYERS 147 CURRENT MOLECULAR DIAGNOSTIC TESTS FOR HUMAN PAPILLOMAVIRUS (HPV) 148 A NEW APPROACH: MESSENGER RNA (MRNA)-BASED DETECTION OF E6/E7 ONCOPROTEINS 148 bioMerieux's Test 148 Roche 149 Innovative Cervical Screening Application Launches in the U.K., and Ireland 150 Quest Diagnostics 150 OncoHealth 151 QIAGEN/Digene 152 Trovagene 152 Becton, Dickinson and Co.: Human Papillomavirus (HPV) Testing and Issues 152 NEW DEVICES 153 Zilico 153 LUMA Cervical Imaging System 154 CHAPTER 9 CERVICAL CANCER PROPHYLACTICS MARKET 156 CERVICAL CANCER VACCINES 156 TABLE 85 VACCINES FOR PREVENTION OF CERVICAL CANCER 156 COMPETITION 156

Therapies and Diagnostics for Cervical Cancer (From Issuu)

Page 10/21


ReportLinker

Find Industry reports, Company profiles and Market Statistics

>> Get this Report Now by email! CERVICAL CANCER PROPHYLACTICS MARKET 157 Preventative Vaccines 157 TABLE 86 GLOBAL CERVICAL CANCER PROPHYLACTICS MARKET: SALES AND FORECAST, THROUGH 2018 ($ MILLIONS) 157 FIGURE 11 GLOBAL CERVICAL CANCER PROPHYLACTICS MARKET: SALES AND FORECAST, 2012-2018 ($ MILLIONS) 157 Vaccine Market: Leaders 158 TABLE 87 KEY COMPANIES: CERVICAL VACCINE MARKET REVENUES AND FORECAST, 2011 AND 2018 ($ MILLIONS) 158 GLOBAL CANCER VACCINES MARKET 159 TABLE 88 GLOBAL VACCINE MARKET: SALES AND FORECAST, THROUGH 2018 ($ MILLIONS) 159 TABLE 89 KEY COMPANIES 159 CANCER VACCINE MARKET: U.S. 160 TABLE 90 U.S. VACCINE MARKET: SALES AND FORECAST, THROUGH 2018 ($ MILLIONS) 160 PROPHYLACTIC VACCINES 160 PROPHYLACTIC CANCER VACCINES MARKET 160 Cervarix 161 TABLE 91 GLOBAL CERVARIX SALES AND FORECAST, THROUGH 2018 ($ MILLIONS) 161 FIGURE 12 GLOBAL CERVARIX SALES AND FORECAST, 2012'2018 ($ MILLIONS) 162 Gardasil 162 TABLE 92 GARDASIL SALES AND FORECAST, 2012 AND 2013 ($ MILLIONS) 163 FIGURE 13 GARDASIL SALES AND FORECAST, 2012 AND 2013 ($ MILLIONS) 163 NEW PRODUCTS 164 VS03 164 TABLE 93 V503 SALES AND FORECAST, 2013 AND 2018 ($ MILLIONS) 164 LATEST DEVELOPMENTS 164 U.K. to Drop Cervarix 164 Cancer Vaccines in Poor Nations 164 CONCLUSIONS 165 CHAPTER 10 THERAPEUTIC MARKET 168 TABLE 94 CERVICAL CANCER THERAPEUTIC MARKET: GLOBAL REVENUE AND FORECASTS, THROUGH 2018 ($ MILLIONS) 168 FIGURE 14 CERVICAL CANCER THERAPEUTIC MARKET: GLOBAL REVENUE AND FORECASTS, 2012-2018 ($ MILLIONS) 168 TREATMENT OF CERVICAL CANCER 169 TABLE 95 TYPES OF SURGERY FOR EARLY CERVICAL CANCER 169 CHEMOTHERAPY MARKET 170 CANCER TREATMENT MARKET 170 CANCER THERAPY 171 TABLE 96 MAJOR PLAYERS 172 Cancer Costs in the U.S. 172 TABLE 97 KEY FACTS: CANCER IN U.S., 2020 172 TABLE 98 U.S.: CERVICAL CANCER PREVALENCE ESTIMATES FOR 2010 AND 2020 (THOUSANDS) 173

Therapies and Diagnostics for Cervical Cancer (From Issuu)

Page 11/21


ReportLinker

Find Industry reports, Company profiles and Market Statistics

>> Get this Report Now by email! TABLE 99 CERVICAL CANCER: CANCER PREVALENCE IN U.S. 173 TABLE 100 CANCER CARE COST IN U.S., 2010 AND 2020 ($ BILLIONS) 174 CYTOTOXIC THERAPIES MARKET 174 TABLE 101 CYTOTOXIC THERAPIES MARKET INDICATIONS 175 TABLE 102 GLOBAL CYTOTHERAPEUTICS MARKET, 2010 AND 2017 ($ MILLIONS) 175 FIGURE 15 GLOBAL CYTOTHERAPEUTICS MARKET, 2010 AND 2017 ($ MILLIONS) 176 TABLE 103 U.S. CYTOTHERAPEUTICS MARKET, THROUGH 2018 ($ MILLIONS) 176 FIGURE 16 U.S. CYTOTHERAPEUTICS MARKET, THROUGH 2018 ($ MILLIONS) 176 TABLE 104 EUROPEAN CYTOTHERAPEUTICS MARKET, THROUGH 2018 ($ MILLIONS) 177 FIGURE 17 EUROPEAN CYTOTHERAPEUTICS MARKET, THROUGH 2018 ($ MILLIONS) 178 TABLE 105 JAPANESE CYTOTHERAPEUTICS MARKET, THROUGH 2018 ($ MILLIONS) 178 FIGURE 18 JAPANESE CYTOTHERAPEUTICS MARKET, 2012-2018 ($ MILLIONS) 179 CERVICAL CHEMOTHERAPY MARKET 179 TABLE 106 CERVICAL CANCER CHEMOTHERAPY MARKET: GLOBAL REVENUE AND FORECASTS, THROUGH 2018 ($ MILLIONS) 179 FIGURE 19 CERVICAL CANCER MARKET: GLOBAL REVENUE AND FORECASTS, 2012-2018 ($ MILLIONS) 179 TABLE 107 CERVICAL CANCER CHEMOTHERAPY MARKET IN U.S.: SALES AND FORECAST, THROUGH 2018 ($ MILLIONS) 180 FIGURE 20 CERVICAL CANCER CHEMOTHERAPY MARKET IN U.S.: SALES AND FORECAST, 2012-2018 ($ MILLIONS) 181 CHEMOTHERAPY AND DRAWBACKS 181 DRUGS USED IN CHEMOTHERAPY 181 TABLE 108 DRUGS APPROVED TO TREAT CERVICAL CANCER 181 Paclitaxel 181 TABLE 109 SALES OF KEY DRUGS FOR CERVICAL CANCER, 2010 ($ MILLIONS) 182 Carboplatin 182 TABLE 110 CARBOPLATIN SALES, 2010'2012 ($ MILLIONS) 182 Taxotere/Docetaxel 182 TABLE 111 TAXOTERE GLOBAL SALES AND FORECAST, 2010-2012 ($ MILLIONS) 183 Gemzar 183 TABLE 112 GEMZAR REVENUE, 2010 AND 2011 ($ MILLIONS) 184 Future for Gemcitabine as a Drug 184 Cisplatin 185 Hycamtin 185 TABLE 113 HYCAMTIN SALES, 2010'2012 ($ MILLIONS) 186 Bleomycin 186 OTHER TREATMENT DRUGS 186 Avastin 186 TABLE 114 AVASTIN SALES AND FORECAST, THROUGH 2018 ($ MILLIONS) 187 CANCER IMMUNOTHERAPY 188 TREATMENT STRATEGIES 189 TABLE 115 CERVICAL CANCER: TREATMENT OPTIONS, 1999'2008 (%) 189 TREATMENT PROCEDURE COST ESTIMATES 190 CERVICAL CANCER SURGERY 191 TABLE 116 CERVICAL CANCER SURGERY MARKET IN U.S.: SALES AND FORECAST, THROUGH 2018 ($ MILLIONS) 191 FIGURE 21 CERVICAL CANCER SURGERY MARKET IN U.S.: SALES AND FORECAST,

Therapies and Diagnostics for Cervical Cancer (From Issuu)

Page 12/21


ReportLinker

Find Industry reports, Company profiles and Market Statistics

>> Get this Report Now by email! 2012-2018 ($ MILLIONS) 192 COSTS OF CERVICAL CANCER SURGERY 192 TABLE 117 SURGERY/HYSTERECTOMY FOR CERVICAL CANCER: GLOBAL SALES AND FORECAST, THROUGH 2018 ($ MILLIONS) 193 FIGURE 22 SURGERY/HYSTERECTOMY FOR CERVICAL CANCER: GLOBAL SALES AND FORECAST, 2012-2018 ($ MILLIONS) 193 TABLE 118 HYSTERECTOMY FOR CERVICAL CANCER IN U.S.: SALES AND FORECAST, THROUGH 2018 ($ MILLIONS) 194 FIGURE 23 HYSTERECTOMY FOR CERVICAL CANCER IN U.S.: SALES AND FORECAST, 2012-2018 ($ MILLIONS) 194 RADIATION THERAPY FOR CERVICAL CANCER 195 Radiation Therapy and Cost Estimates 195 TABLE 119 CERVICAL CANCER RADIATION THERAPY MARKET: GLOBAL SALES AND FORECAST, THROUGH 2018 ($ MILLIONS) 196 FIGURE 24 CERVICAL CANCER RADIATION THERAPY MARKET: GLOBAL-SALES AND FORECAST, 2012-2018 ($ MILLIONS) 196 TABLE 120 CERVICAL CANCER RADIATION THERAPY MARKET IN U.S.: SALES AND FORECAST, THROUGH 2018 ($ MILLIONS) 197 FIGURE 25 CERVICAL CANCER RADIATION THERAPY MARKET IN U.S.: SALES AND FORECAST, 2012-2018 ($ MILLIONS) 197 CONCLUSIONS 197 TABLE 121 KEY FACTS ABOUT CERVICAL CANCER 198 CHAPTER 11 PATENT LANDSCAPE 201 TABLE 122 CERVICAL CANCER VACCINE PATENTS (%) 201 GLOBAL IMPACT OF PATENT EXPIRIES 201 PATENT LANDSCAPE 202 Hycamtin (Topotecan Hydrochloride) 203 Gemzar 203 TABLE 123 CERVICAL CANCER CHEMOTHERAPY DRUGS: PATENT EXPIRY 203 Doxil 204 Cisplatin 204 Avastin 204 CHAPTER 12 SELECTED COMPANY PROFILES 206 ABBOTT LABORATORIES 206 ADVAXIS 206 ASTRAZENECA 206 BECTON, DICKENSON AND CO. 207 BRISTOL-MYERS SQUIBB 207 DIGENE CORP. 207 DENDREON CORP. 208 FEMASYS 208 GLAXOSMITHKLINE 208 HOLOGIC 208 ISA PHARMACEUTICALS 209

Therapies and Diagnostics for Cervical Cancer (From Issuu)

Page 13/21


ReportLinker

Find Industry reports, Company profiles and Market Statistics

>> Get this Report Now by email! JOHNSON & JOHNSON 209 MERCK 210 ONCOHEALTH CORP. 210 PFIZER 210 QUEST DIAGNOSTICS 211 QIAGEN 212 ROCHE DIAGNOSTICS 212 SANOFI 212 TAJ PHARMACEUTICALS 213 TEVA PHARMACEUTICAL INDUSTRIES 213 TROVAGENE 213 ZILICO LTD. 214 CHAPTER 13 REFERENCES 216

LIST OF TABLES SUMMARY TABLE CERVICAL CANCER: GLOBAL MARKET FOR DRUGS AND DIAGNOSTICS, THROUGH 2018 ($ MILLIONS) 7 TABLE 1 MAIN TYPES OF CANCER AND MORTALITY 10 TABLE 2 CANCER: KEY FACTS 11 TABLE 3 PREVENTION STRATEGIES 11 TABLE 4 CURRENT SCREENING METHODS 12 TABLE 5 NONCOMMUNICABLE DISEASES ACTION PLAN 13 TABLE 6 HISTORY 14 TABLE 7 CERVICAL CANCER SYMPTOMS 16 TABLE 8 ADVANCED CERVICAL CANCER SYMPTOMS 16 TABLE 9 DIAGNOSIS OF CERVICAL CANCER 17 TABLE 10 RISK FACTORS FOR CERVICAL CANCER 17 TABLE 11 CERVICAL CANCER STAGING 18 TABLE 12 HUMAN PAPILLOMAVIRUS: TYPES 23 TABLE 13 HISTOLOGIC SUBTYPES OF INVASIVE CERVICAL CARCINOMA 30 TABLE 14 NON-CARCINOMA MALIGNANCIES THAT CAN RARELY OCCUR IN THE CERVIX 30 TABLE 15 THE MAJOR CATEGORIES OF THE INTERNATIONAL FEDERATION OF GYNECOLOGY AND OBSTETRICS (FIGO) CLASSIFICATION 39 TABLE 16 THE INTERNATIONAL FEDERATION OF GYNECOLOGY AND OBSTETRICS (FIGO) STAGES 40 TABLE 17 TWO SCREENING TESTS THAT HELP PREVENT CERVICAL CANCER OR DETECT IT EARLY 41 TABLE 18 TYPES OF SCREENING FOR CERVICAL CANCER 43 TABLE 19 PAP TEST INDICATIONS 43 TABLE 20 BETHESDA SYSTEM 45 TABLE 21 FDA-APPROVED HUMAN PAPILLOMAVIRUS (HPV) TESTS 47 TABLE 22 CERVICAL CANCER SCREENING 52 TABLE 23 THE ACS-ASCCP-ASCP RECOMMENDATIONS: CHANGES FROM THE

Therapies and Diagnostics for Cervical Cancer (From Issuu)

Page 14/21


ReportLinker

Find Industry reports, Company profiles and Market Statistics

>> Get this Report Now by email! PREVIOUS ACS GUIDELINES 54 TABLE 24 IMPORTANT GYNECOLOGIC TUMOR MARKERS 55 TABLE 25 OTHER POTENTIAL GYNECOLOGIC TUMOR MARKERS 55 TABLE 26 THE BETHESDA SYSTEM 60 TABLE 27 DRUGS APPROVED TO TREAT CERVICAL CANCER 65 TABLE 28 COMMON CHEMOTHERAPY MEDICINES USED TO TREAT CERVICAL CANCER 65 TABLE 29 POPULATION MEASURES AND CANCER INCIDENCE AND MORTALITY IN REGIONS OF THE WORLD, ESTIMATES 2008'2010 75 TABLE 30 TOTAL NUMBER AND PERCENTAGES OF ALL CANCER DEATHS, WORLDWIDE, 2008 77 TABLE 31 THE PROJECTED PERCENTAGE CHANGE IN EUROPEAN AGE-STANDARDIZED CANCER INCIDENCE RATES PER 100,000 POPULATION, U.K., 2007'2030 79 TABLE 32 POPULATION ATTRIBUTABLE FRACTION (%) 80 TABLE 33 CERVICAL CANCER: GLOBAL INCIDENCE, 2008 81 TABLE 34 GLOBAL CERVICAL CANCER: MORTALITY 2008 AND 2030* 82 TABLE 35 WORLDWIDE PREVALENCE OF HUMAN PAPILLOMAVIRUS (HPV) IN WOMEN WITH CERVICAL CANCER 83 TABLE 36 CERVICAL CANCER BY CONTINENTS, 2008 ESTIMATES 85 TABLE 37 CERVICAL CANCER WORLD AGE-STANDARDIZED INCIDENCE RATES PER 100,000 POPULATION, FEMALES IN WORLD REGIONS, 2008 ESTIMATES 85 TABLE 38 CERVICAL CANCER INCIDENCE AND MORTALITY WORLDWIDE, 2008 (THOUSANDS) 86 TABLE 39 WORLDWIDE BURDEN OF CERVICAL CANCER BY AREA, 2008 89 TABLE 40 CHANGING TRENDS IN CANCER-SPECIFIC AGE-ADJUSTED INCIDENCE (%) 90 TABLE 41 U.S.: ESTIMATED NEW CASES AND DEATHS FROM CERVICAL (UTERINE CERVIX) CANCER, 2012 AND 2013 94 TABLE 42 U.S.: INCIDENCE RATES BY RACE, 2005'2009 95 TABLE 43 U.S.: DEATH RATES BY RACE, 2005-2009 95 TABLE 44 STAGE DISTRIBUTION AND FIVE-YEAR RELATIVE SURVIVAL BY STAGE AT DIAGNOSIS, ALL RACES, FEMALES, 2002'2008 96 TABLE 45 FIVE-YEAR OBSERVED SURVIVAL RATE 97 TABLE 46 CERVICAL CANCER: EUROPEAN AGE-STANDARDIZED INCIDENCE RATES PER 100,000 POPULATION AMONG FEMALES, EU27 COUNTRIES, 2008 ESTIMATES 98 TABLE 47 NUMBER OF NEW CASES AND CRUDE AND EUROPEAN AGE-STANDARDIZED (AS) INCIDENCE RATES PER 100,000 POPULATION AMONG FEMALES IN U.K., 2009 100 TABLE 48 CERVICAL CANCER: AVERAGE NUMBER OF NEW CASES PER YEAR AND AGE-SPECIFIC INCIDENCE RATES PER 100,000 POPULATION AMONG FEMALES IN U.K., 2007'2009 101 TABLE 49 CERVICAL CANCER: PERCENTAGE CHANGE IN AGE-SPECIFIC INCIDENCE RATES PER 100,000 POPULATION AMONG FEMALES IN U.K., 2008'2009 102 TABLE 50 CERVICAL CANCER: ONE-YEAR, FIVE-YEAR, AND 10-YEAR CANCER PREVALENCE AMONG FEMALES IN U.K., DECEMBER 31, 2006 102 TABLE 51 NUMBER OF NEW CASES IN U.K., 2009 AND 2010 103

Therapies and Diagnostics for Cervical Cancer (From Issuu)

Page 15/21


ReportLinker

Find Industry reports, Company profiles and Market Statistics

>> Get this Report Now by email! TABLE 52 U.K.: THE 10 MOST COMMONLY DIAGNOSED CANCERS IN FEMALES IN 1984, 2007, AND 2030 104 TABLE 53 CERVICAL CANCER: THE PROJECTED PERCENTAGE CHANGE IN EUROPEAN AGE-STANDARDIZED MORTALITY RATES PER 100,000 POPULATION IN U.K., 2010 AND 2030 104 TABLE 54 U.K.: THE 10 MOST COMMON CAUSES OF CANCER DEATH IN FEMALES IN 1990, 2010, AND 2030 105 TABLE 55 KEY STATISTICS IN AFRICA AND ITS REGIONS, 2008 109 TABLE 56 HUMAN PAPILLOMAVIRUS (HPV) PREVALENCE IN THE GENERAL POPULATION, 2008 110 TABLE 57 AFRICA: PREVALENCE HPV 16 AND/OR HPV 18 AMONG WOMEN WITH THE FOLLOWING CHARACTERISTICS 110 TABLE 58 INCIDENCE OF CERVICAL CANCER IN AFRICA BY REGION, 2008 111 TABLE 59 MORTALITY OF CERVICAL CANCER IN AFRICA BY REGION, 2008 111 TABLE 60 AGE-STANDARDIZED INCIDENCE RATES OF CERVICAL CANCER IN AFRICA, 2008 111 TABLE 61 AGE-STANDARDIZED MORTALITY RATES OF CERVICAL CANCER IN AFRICA, 2008 112 TABLE 62 INCIDENCE OF CERVICAL CANCER IN GERMANY, WESTERN EUROPE, AND THE WORLD, 2008 (RATES PER 100,000 WOMEN PER YEAR) 117 TABLE 63 KEY STATISTICS ON GERMANY, 2010-2025 117 TABLE 64 AUSTRALIA: PROJECTED COMMON CANCERS IN FEMALES, 2020 118 TABLE 65 AUSTRALIA: PROJECTED NUMBER OF NEW CERVICAL CANCER CASES AND AGE-STANDARDIZED RATES AMONG FEMALES WITH 95% PREDICTION INTERVALS, 2011-2020 119 TABLE 66 AUSTRALIA: PROJECTED CERVICAL CANCER STATISTICS, 2020 119 TABLE 67 WOMEN UNDERGOING CERVICAL CANCER SCREENING 123 TABLE 68 WORLDWIDE CERVICAL CANCER DIAGNOSTIC MARKET, THROUGH 2018 ($ MILLIONS) 125 TABLE 69 MARKET DRIVERS 126 TABLE 70 KEY PLAYERS 127 TABLE 71 GLOBAL CERVICAL CANCER DIAGNOSTIC TESTS: PAP SMEAR TESTS MARKET AND FORECAST, THROUGH 2018 ($ MILLIONS) 131 TABLE 72 NUMBER OF PAP SMEAR TESTS PERFORMED IN THE U.S. AND EUROPE, 2012 AND 2013 (MILLIONS) 133 TABLE 73 U.S.: PERCENT OF PAP SMEAR TESTS PERFORMED, 2008 AND 2010 (%) 133 TABLE 74 U.S.: PERCENT OF WOMEN WHO RECEIVE PAP SMEAR TESTS, AGE-STRATIFIED, 2008 AND 2010 (%) 134 TABLE 75 PAP TESTS ORDERED OR PROVIDED IN U.S., 2010 134 TABLE 76 PAP TESTS ORDERED OR PROVIDED AT OUTPATIENT DEPARTMENT VISITS IN U.S., 2010 135 TABLE 77 ABNORMALITIES OF THE CERVIX 138 TABLE 78 WORLDWIDE ESTIMATED NUMBER OF COLPOSCOPY PROCEDURE TESTS PERFORMED, 2012-2018 (MILLIONS) 139 TABLE 79 CERVICAL CANCER COLPOSCOPY: GLOBAL MARKET AND FORECAST, THROUGH 2018 ($ MILLIONS) 140

Therapies and Diagnostics for Cervical Cancer (From Issuu)

Page 16/21


ReportLinker

Find Industry reports, Company profiles and Market Statistics

>> Get this Report Now by email! TABLE 80 CERVICAL CANCER: COLPOSCOPY TESTS MARKET AND FORECAST IN U.S., THROUGH 2018 ($ MILLIONS) 140 TABLE 81 TYPES OF CERVICAL BIOPSIES 142 TABLE 82 WORLDWIDE ENDOCERVICAL CURETTAGE (ECC) PROCEDURE MARKET: SALES AND FORECAST, THROUGH 2018 ($ MILLIONS) 144 TABLE 83 WORLDWIDE HUMAN PAPILLOMAVIRUS (HPV) TESTING MARKET: SALES AND FORECAST, THROUGH 2018 ($ MILLIONS) 146 TABLE 84 KEY PLAYERS 147 TABLE 85 VACCINES FOR PREVENTION OF CERVICAL CANCER 156 TABLE 86 GLOBAL CERVICAL CANCER PROPHYLACTICS MARKET: SALES AND FORECAST, THROUGH 2018 ($ MILLIONS) 157 TABLE 87 KEY COMPANIES: CERVICAL VACCINE MARKET REVENUES AND FORECAST, 2011 AND 2018 ($ MILLIONS) 158 TABLE 88 GLOBAL VACCINE MARKET: SALES AND FORECAST, THROUGH 2018 ($ MILLIONS) 159 TABLE 89 KEY COMPANIES 159 TABLE 90 U.S. VACCINE MARKET: SALES AND FORECAST, THROUGH 2018 ($ MILLIONS) 160 TABLE 91 GLOBAL CERVARIX SALES AND FORECAST, THROUGH 2018 ($ MILLIONS) 161 TABLE 92 GARDASIL SALES AND FORECAST, 2012 AND 2013 ($ MILLIONS) 163 TABLE 93 V503 SALES AND FORECAST, 2013 AND 2018 ($ MILLIONS) 164 TABLE 94 CERVICAL CANCER THERAPEUTIC MARKET: GLOBAL REVENUE AND FORECASTS, THROUGH 2018 ($ MILLIONS) 168 TABLE 95 TYPES OF SURGERY FOR EARLY CERVICAL CANCER 169 TABLE 96 MAJOR PLAYERS 172 TABLE 97 KEY FACTS: CANCER IN U.S., 2020 172 TABLE 98 U.S.: CERVICAL CANCER PREVALENCE ESTIMATES FOR 2010 AND 2020 (THOUSANDS) 173 TABLE 99 CERVICAL CANCER: CANCER PREVALENCE IN U.S. 173 TABLE 100 CANCER CARE COST IN U.S., 2010 AND 2020 ($ BILLIONS) 174 TABLE 101 CYTOTOXIC THERAPIES MARKET INDICATIONS 175 TABLE 102 GLOBAL CYTOTHERAPEUTICS MARKET, 2010 AND 2017 ($ MILLIONS) 175 TABLE 103 U.S. CYTOTHERAPEUTICS MARKET, THROUGH 2018 ($ MILLIONS) 176 TABLE 104 EUROPEAN CYTOTHERAPEUTICS MARKET, THROUGH 2018 ($ MILLIONS) 177 TABLE 105 JAPANESE CYTOTHERAPEUTICS MARKET, THROUGH 2018 ($ MILLIONS) 178 TABLE 106 CERVICAL CANCER CHEMOTHERAPY MARKET: GLOBAL REVENUE AND FORECASTS, THROUGH 2018 ($ MILLIONS) 179 TABLE 107 CERVICAL CANCER CHEMOTHERAPY MARKET IN U.S.: SALES AND FORECAST, THROUGH 2018 ($ MILLIONS) 180 TABLE 108 DRUGS APPROVED TO TREAT CERVICAL CANCER 181 TABLE 109 SALES OF KEY DRUGS FOR CERVICAL CANCER, 2010 ($ MILLIONS) 182 TABLE 110 CARBOPLATIN SALES, 2010'2012 ($ MILLIONS) 182 TABLE 111 TAXOTERE GLOBAL SALES AND FORECAST, 2010-2012 ($ MILLIONS) 183 TABLE 112 GEMZAR REVENUE, 2010 AND 2011 ($ MILLIONS) 184 TABLE 113 HYCAMTIN SALES, 2010'2012 ($ MILLIONS) 186 TABLE 114 AVASTIN SALES AND FORECAST, THROUGH 2018 ($ MILLIONS) 187 TABLE 115 CERVICAL CANCER: TREATMENT OPTIONS, 1999'2008 (%) 189 TABLE 116 CERVICAL CANCER SURGERY MARKET IN U.S.: SALES AND FORECAST,

Therapies and Diagnostics for Cervical Cancer (From Issuu)

Page 17/21


ReportLinker

Find Industry reports, Company profiles and Market Statistics

>> Get this Report Now by email! THROUGH 2018 ($ MILLIONS) 191 TABLE 117 SURGERY/HYSTERECTOMY FOR CERVICAL CANCER: GLOBAL SALES AND FORECAST, THROUGH 2018 ($ MILLIONS) 193 TABLE 118 HYSTERECTOMY FOR CERVICAL CANCER IN U.S.: SALES AND FORECAST, THROUGH 2018 ($ MILLIONS) 194 TABLE 119 CERVICAL CANCER RADIATION THERAPY MARKET: GLOBAL SALES AND FORECAST, THROUGH 2018 ($ MILLIONS) 196 TABLE 120 CERVICAL CANCER RADIATION THERAPY MARKET IN U.S.: SALES AND FORECAST, THROUGH 2018 ($ MILLIONS) 197 TABLE 121 KEY FACTS ABOUT CERVICAL CANCER 198 TABLE 122 CERVICAL CANCER VACCINE PATENTS (%) 201 TABLE 123 CERVICAL CANCER CHEMOTHERAPY DRUGS: PATENT EXPIRY 203

LIST OF FIGURES SUMMARY FIGURE CERVICAL CANCER: GLOBAL MARKET FOR DRUGS AND DIAGNOSTICS, 2012-2018 ($ MILLIONS) 8 FIGURE 1 MAIN TYPES OF CANCER AND MORTALITY 10 FIGURE 2 CERVICAL CANCER INCIDENCE AND MORTALITY WORLDWIDE, 2008 (THOUSANDS) 86 FIGURE 3 CERVICAL CANCER: EUROPEAN AGE-STANDARDIZED INCIDENCE RATES PER 100,000 POPULATION AMONG FEMALES, EU27 COUNTRIES, 2008 ESTIMATES 98 FIGURE 4 WORLDWIDE CERVICAL CANCER DIAGNOSTIC MARKET, 2012-2018 ($ MILLIONS) 125 FIGURE 5 GLOBAL CERVICAL CANCER DIAGNOSTIC TESTS: PAP SMEAR TESTS MARKET AND FORECAST, 2012-2018 ($ MILLIONS) 131 FIGURE 6 WORLDWIDE ESTIMATED NUMBER OF COLPOSCOPY PROCEDURE TESTS PERFORMED, 2012'2018 (MILLIONS) 139 FIGURE 7 CERVICAL CANCER COLPOSCOPY: GLOBAL MARKET AND FORECAST, 2012-2018 ($ MILLIONS) 140 FIGURE 8 CERVICAL CANCER: COLPOSCOPY TESTS MARKET AND FORECAST IN U.S., 2012-2018 ($ MILLIONS) 141 FIGURE 9 WORLDWIDE ENDOCERVICAL CURETTAGE (ECC) PROCEDURE MARKET: SALES AND FORECAST, 2012-2018 ($ MILLIONS) 144 FIGURE 10 WORLDWIDE HUMAN PAPILLOMAVIRUS (HPV) TESTING MARKET: SALES AND FORECAST, 2012-2018 ($ MILLIONS) 146 FIGURE 11 GLOBAL CERVICAL CANCER PROPHYLACTICS MARKET: SALES AND FORECAST, 2012-2018 ($ MILLIONS) 157 FIGURE 12 GLOBAL CERVARIX SALES AND FORECAST, 2012'2018 ($ MILLIONS) 162 FIGURE 13 GARDASIL SALES AND FORECAST, 2012 AND 2013 ($ MILLIONS) 163 FIGURE 14 CERVICAL CANCER THERAPEUTIC MARKET: GLOBAL REVENUE AND FORECASTS, 2012-2018 ($ MILLIONS) 168 FIGURE 15 GLOBAL CYTOTHERAPEUTICS MARKET, 2010 AND 2017 ($ MILLIONS) 176 FIGURE 16 U.S. CYTOTHERAPEUTICS MARKET, THROUGH 2018 ($ MILLIONS) 176 FIGURE 17 EUROPEAN CYTOTHERAPEUTICS MARKET, THROUGH 2018 ($ MILLIONS) 178 FIGURE 18 JAPANESE CYTOTHERAPEUTICS MARKET, 2012-2018 ($ MILLIONS) 179

Therapies and Diagnostics for Cervical Cancer (From Issuu)

Page 18/21


ReportLinker

Find Industry reports, Company profiles and Market Statistics

>> Get this Report Now by email! FIGURE 19 CERVICAL CANCER MARKET: GLOBAL REVENUE AND FORECASTS, 2012-2018 ($ MILLIONS) 179 FIGURE 20 CERVICAL CANCER CHEMOTHERAPY MARKET IN U.S.: SALES AND FORECAST, 2012-2018 ($ MILLIONS) 181 FIGURE 21 CERVICAL CANCER SURGERY MARKET IN U.S.: SALES AND FORECAST, 2012-2018 ($ MILLIONS) 192 FIGURE 22 SURGERY/HYSTERECTOMY FOR CERVICAL CANCER: GLOBAL SALES AND FORECAST, 2012-2018 ($ MILLIONS) 193 FIGURE 23 HYSTERECTOMY FOR CERVICAL CANCER IN U.S.: SALES AND FORECAST, 2012-2018 ($ MILLIONS) 194 FIGURE 24 CERVICAL CANCER RADIATION THERAPY MARKET: GLOBAL-SALES AND FORECAST, 2012-2018 ($ MILLIONS) 196 FIGURE 25 CERVICAL CANCER RADIATION THERAPY MARKET IN U.S.: SALES AND FORECAST, 2012-2018 ($ MILLIONS) 197

Therapies and Diagnostics for Cervical Cancer (From Issuu)

Page 19/21


Find Industry reports, Company profiles and Market Statistics

ReportLinker

>> Get this Report Now by email! Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to: ƒ ƒ

Europe, Middle East and Africa : + 33 4 37 37 15 56 Asia, Oceania and America : + 1 (805) 617 17 93

If you have any questions please visit http://www.reportlinker.com/notify/contact

Order Information Please verify that the product information is correct and select the format(s) you require. Therapies and Diagnostics for Cervical Cancer

Product Formats Please select the product formats and the quantity you require. 1 User License--USD 5 450.00

Quantity: _____

Department License--USD 6 650.00

Quantity: _____

Corporate License--USD 9 350.00

Quantity: _____

Contact Information Please enter all the information below in BLOCK CAPITALS

Title:

Mr

Mrs

Dr

Miss

Ms

Prof

First Name:

_____________________________ Last Name: __________________________________

Email Address:

__________________________________________________________________________

Job Title:

__________________________________________________________________________

Organization:

__________________________________________________________________________

Address:

__________________________________________________________________________

City:

__________________________________________________________________________

Postal / Zip Code:

__________________________________________________________________________

Country:

__________________________________________________________________________

Phone Number:

__________________________________________________________________________

Fax Number:

__________________________________________________________________________

Therapies and Diagnostics for Cervical Cancer (From Issuu)

Page 20/21


Find Industry reports, Company profiles and Market Statistics

ReportLinker

>> Get this Report Now by email! Payment Information Please indicate the payment method, you would like to use by selecting the appropriate box.

Payment by credit card

Card Number: ______________________________________________

Expiry Date

__________ / _________

CVV Number _____________________

Card Type (ex: Visa, Amex…) _________________________________

Payment by wire transfer

Crédit Mutuel RIB : 10278 07314 00020257701 89 BIC : CMCIFR2A IBAN : FR76 1027 8073 1400 0202 5770 189

Payment by check

UBIQUICK SAS 16 rue Grenette – 69002 LYON, FRANCE

Customer signature:

 

Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at http://www.reportlinker.com/index/terms

Please fax this form to: Europe, Middle East and Africa : + 33 4 37 37 15 56

ƒ ƒ

Therapies and Diagnostics for Cervical Cancer (From Issuu)

Asia, Oceania and America : + 1 (805) 617 17 93

Page 21/21


Therapies and Diagnostics for Cervical Cancer